Alligator Bioscience AB

Equities

ATORX

SE0000767188

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 09:30:01 17/07/2024 pm IST			5-day change	1st Jan Change
1.2 ^SEK	-1.64%		+3.27%	+74.17%

11/07	Transcript : Alligator Bioscience AB, Q2 2024 Earnings Call, Jul 11, 2024
11/07	Alligator Bioscience AB Appoints Johan Giléus as Chief Financial Officer as of August 12, 2024	CI

Alligator Bioscience AB Appoints Anu Balendran as New Vice President Business Development, Effective 1 May 2018

January 18, 2018 at 01:08 pm IST

Alligator Bioscience announced the appointment of Anu Balendran, PhD, as Vice President Business Development. Dr. Balendran will be responsible for leading Alligator's preclinical projects towards out-licensing. He will assume his new role on 1 May 2018.

Latest news about Alligator Bioscience AB

Transcript : Alligator Bioscience AB, Q2 2024 Earnings Call, Jul 11, 2024	11/07
Alligator Bioscience AB Appoints Johan Giléus as Chief Financial Officer as of August 12, 2024	11/07	CI
Alligator Bioscience AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	11/07	CI
Alligator Bioscience Announces Completion of Enrollment in Mitazalimab Optimize-1 Study	10/07	CI
Alligator Bioscience Announces Results from the Ongoing Optimize-1 Trial	26/06	CI
Alligator Bioscience AB to Present Positive Phase 2 Data on Mitazalimab in Pancreatic Cancer at ESMO GI 2024	20/06	CI
Alligator Bioscience Names New CFO	14/06	MT
Alligator Bioscience Announces Publication of on Its Lead Drug Candidate Positive Phase 2 Data Mitazalimab in First Line Metastatic Pancreatic Cancer in the Lancet Oncology	03/06	CI
Alligator Bioscience to Present Positive Phase 2 Mitazalimab Data in Pancreatic Cancer at 2024 ASCO Annual Meeting	24/05	CI
US FDA Grants Investigational New Drug Clearance for Alligator Bioscience's Late-stage Gastric Cancer Treatment Trial	21/05	MT
Alligator Bioscience Announces Initiation of an Investigator-Initiated Phase 1 Clinical Study of Mitazalimab in Local Advanced Pancreatic Cancer	14/05	CI
Transcript : Alligator Bioscience AB, Q1 2024 Earnings Call, May 06, 2024	06/05
Alligator Bioscience AB Reports Earnings Results for the First Quarter Ended March 31, 2024	06/05	CI
Alligator Bioscience and Orion Corporation Announces Exercise of Development Option Under 2021 Research Collaboration and License Agreement	26/04	CI
Alligator Bioscience AB Announces Graham Dixon and Veronica Wallin Not Proposed for Re-Election on Board	05/04	CI
Alligator Bioscience Announces Publication of a Scientific Article Featuring Its Novel Bispecific Antibody Format RUBY® in the Peer-Reviewed Journal mAbs	26/03	CI
Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4	07/03	CI
Transcript : Alligator Bioscience AB, 2023 Earnings Call, Feb 09, 2024	09/02
Correction: Alligator Bioscience Seeks SEK151 Million Capital Raising, Enters SEK59 Million Bridge Loan	09/02	MT
Alligator Bioscience Seeks SEK151 Capital Raising, Enters SEK59 Million Bridge Loan	09/02	MT
Alligator Bioscience to Trim Workforce Amid Restructuring Program	08/02	MT
Alligator Bioscience AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	08/02	CI
Alligator Bioscience Plans to Adjust Size of Organization with Reduction of Approximately 20% to 25% of Current Workforce	08/02	CI
Alligator Bioscience Announces Cost Reduction Program to Align Key Priorities and Maximize Long-Term Value Creation	08/02	CI
Transcript : Alligator Bioscience AB - Special Call	29/01

Chart Alligator Bioscience AB

Duration

Period

More charts

Company Profile

Alligator Bioscience AB is a Sweden-based biotechnology Company that develops antibody-based drugs for cancer treatment. The Company specializes in the development of tumor-targeted immunotherapies, in particular agonist mono- and bispecific antibodies, and is active in the early stages of drug development, from concept to phase II clinical trials. Alligatorâs pipeline includes the two key assets mitazalimab, a CD40 agonist, and ATOR-1017, a 4-1BB agonist. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its technology platform, Neo-X-Prime, with MacroGenics Inc. and drug candidates based on the RUBY bispecific platform with Orion Corporation. Its licensed programs include AC101, in phase II development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. The Company operates domestically.

Sector

Biotechnology & Medical Research

Calendar

24/10/2024 - Q3 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Alligator Bioscience AB

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.2 SEK

Average target price

1.933 SEK

Spread / Average Target

+61.11%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ALLIGATOR BIOSCIENCE AB	+74.17%	86.27M
MODERNA, INC.	+24.74%	47.54B
IQVIA HOLDINGS INC.	-0.47%	41.96B
LONZA GROUP AG	+43.96%	41.55B
ALNYLAM PHARMACEUTICALS, INC.	+25.40%	30.36B
ICON PUBLIC LIMITED COMPANY	+17.96%	27.61B
CELLTRION, INC.	-4.47%	28.7B
UNITED THERAPEUTICS CORPORATION	+50.73%	14.7B
MEDPACE HOLDINGS, INC.	+42.56%	13.51B
BIO-TECHNE CORPORATION	+1.46%	12.34B

Other Biotechnology & Medical Research